NO331618B1 - Nye 3-(4-okso-4H-kromen-2-yl)-(1H)-kinolin-4-on-forbindelser, en fremgangsmate for deres fremstilling og farmasoytisk sammensetninger inneholdende dem - Google Patents

Nye 3-(4-okso-4H-kromen-2-yl)-(1H)-kinolin-4-on-forbindelser, en fremgangsmate for deres fremstilling og farmasoytisk sammensetninger inneholdende dem Download PDF

Info

Publication number: NO331618B1
Authority: NO; Norway
Prior art keywords: compound; formula; phenyl; oxo; give
Prior art date: 2002-06-19

Application number

NO20045540A

Other languages

English (en)

Norwegian (no)

Other versions

NO20045540L (no

Inventor

Jean-Daniel Brion

Catherine Harpey

Alain Le Ridant

Lucien Israel

Cherif Rabhi

El Bachir Kaloun

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-19

Filing date

2004-12-17

Publication date

2012-02-06

2004-12-17 Application filed by Servier Lab filed Critical Servier Lab

2004-12-17 Publication of NO20045540L publication Critical patent/NO20045540L/no

2012-02-06 Publication of NO331618B1 publication Critical patent/NO331618B1/no

Links

238000000034 method Methods 0.000 title claims description 21
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
238000002360 preparation method Methods 0.000 title claims description 6
SNBIWTMXVCJJJZ-UHFFFAOYSA-N 3-(4-oxochromen-2-yl)-1h-quinolin-4-one Chemical class C1=CC=C2C(=O)C(C3=CC(C4=CC=CC=C4O3)=O)=CNC2=C1 SNBIWTMXVCJJJZ-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 79
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 9
239000002253 acid Substances 0.000 claims abstract description 7
125000003118 aryl group Chemical group 0.000 claims abstract description 7
239000001257 hydrogen Substances 0.000 claims abstract description 7
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
150000003839 salts Chemical class 0.000 claims abstract description 5
150000004677 hydrates Chemical class 0.000 claims abstract description 3
239000012453 solvate Substances 0.000 claims abstract description 3
125000000217 alkyl group Chemical group 0.000 claims abstract 4
239000000203 mixture Substances 0.000 claims description 12
239000002246 antineoplastic agent Substances 0.000 claims description 10
-1 1,2,5,6-tetrahydropyridin-4-yl Chemical group 0.000 claims description 8
230000002378 acidificating effect Effects 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 4
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 2
YBTLURAJRGMOQC-UHFFFAOYSA-N 3-(5-hydroxy-4-oxochromen-2-yl)-1-phenylquinolin-4-one Chemical compound C=1C(=O)C=2C(O)=CC=CC=2OC=1C(C(C1=CC=CC=C11)=O)=CN1C1=CC=CC=C1 YBTLURAJRGMOQC-UHFFFAOYSA-N 0.000 claims description 2
125000001624 naphthyl group Chemical group 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
238000000746 purification Methods 0.000 claims description 2
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 2
229940041181 antineoplastic drug Drugs 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
125000003545 alkoxy group Chemical group 0.000 abstract description 3
239000003814 drug Substances 0.000 abstract description 3
229940079593 drug Drugs 0.000 abstract description 2
125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 abstract 1
125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
238000002483 medication Methods 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
230000003287 optical effect Effects 0.000 abstract 1
239000001301 oxygen Chemical group 0.000 abstract 1
229910052760 oxygen Chemical group 0.000 abstract 1
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 39
239000000047 product Substances 0.000 description 26
238000002844 melting Methods 0.000 description 23
230000008018 melting Effects 0.000 description 23
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
238000004452 microanalysis Methods 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 11
210000004027 cell Anatomy 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
238000011282 treatment Methods 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 6
UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 6
229960000583 acetic acid Drugs 0.000 description 6
239000012298 atmosphere Substances 0.000 description 6
230000001472 cytotoxic effect Effects 0.000 description 6
201000011510 cancer Diseases 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
230000006907 apoptotic process Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
229930012538 Paclitaxel Natural products 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
229960004316 cisplatin Drugs 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000004821 distillation Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229960001592 paclitaxel Drugs 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
MLIBGOFSXXWRIY-UHFFFAOYSA-N 1-(2-hydroxy-5-methoxyphenyl)ethanone Chemical compound COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 2
IZXWCDITFDNEBY-UHFFFAOYSA-N 1-(chloromethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCl)C=C1 IZXWCDITFDNEBY-UHFFFAOYSA-N 0.000 description 2
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
238000000605 extraction Methods 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
239000002198 insoluble material Substances 0.000 description 2
229960004768 irinotecan Drugs 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000000861 pro-apoptotic effect Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
SQMIXHCJWRQFCT-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperidin-4-one Chemical compound C1=CC(F)=CC=C1CN1CCC(=O)CC1 SQMIXHCJWRQFCT-UHFFFAOYSA-N 0.000 description 1
YNLPCMOMSMGFLQ-UHFFFAOYSA-N 1-[2-hydroxy-4,6-dimethoxy-3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)phenyl]ethanone Chemical compound OC1=C(C(C)=O)C(OC)=CC(OC)=C1C1=CCN(C)CC1 YNLPCMOMSMGFLQ-UHFFFAOYSA-N 0.000 description 1
SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
CCDBCHAQIXKJCG-UHFFFAOYSA-N 1-propan-2-ylpiperidin-4-one Chemical compound CC(C)N1CCC(=O)CC1 CCDBCHAQIXKJCG-UHFFFAOYSA-N 0.000 description 1
PMZDQRJGMBOQBF-UHFFFAOYSA-N 1H-quinolin-4-one Natural products C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
UENLHUMCIOWYQN-UHFFFAOYSA-N 2'-Hydroxy-6'-methoxyacetophenone Chemical compound COC1=CC=CC(O)=C1C(C)=O UENLHUMCIOWYQN-UHFFFAOYSA-N 0.000 description 1
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
ATEVJWGDEIQLQL-UHFFFAOYSA-N 3-(4-oxochromen-2-yl)-1-phenylquinolin-4-one Chemical compound O1C2=CC=CC=C2C(=O)C=C1C(C(C1=CC=CC=C11)=O)=CN1C1=CC=CC=C1 ATEVJWGDEIQLQL-UHFFFAOYSA-N 0.000 description 1
MWRFTDPSWSZLAW-UHFFFAOYSA-N 3-(7-hydroxy-4-oxochromen-2-yl)-1-phenylquinolin-4-one Chemical compound C=1C(O)=CC=C(C(C=2)=O)C=1OC=2C(C(C1=CC=CC=C11)=O)=CN1C1=CC=CC=C1 MWRFTDPSWSZLAW-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
229910015845 BBr3 Inorganic materials 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
206010061188 Haematotoxicity Diseases 0.000 description 1
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
102100038042 Retinoblastoma-associated protein Human genes 0.000 description 1
101710124357 Retinoblastoma-associated protein Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
231100000226 haematotoxicity Toxicity 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
SXWRTZOXMUOJER-UHFFFAOYSA-N hydron;piperidin-4-one;chloride;hydrate Chemical compound O.Cl.O=C1CCNCC1 SXWRTZOXMUOJER-UHFFFAOYSA-N 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
VSGPVHSTVTXREH-UHFFFAOYSA-N quinolin-4-one Chemical compound C1=CC=C[C]2C(=O)C=CN=C21 VSGPVHSTVTXREH-UHFFFAOYSA-N 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
FBUBVLUPUDBFME-UHFFFAOYSA-N xanthoxylline Natural products COC1=CC(O)=C(C(C)=O)C(OC)=C1 FBUBVLUPUDBFME-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20045540A 2002-06-19 2004-12-17 Nye 3-(4-okso-4H-kromen-2-yl)-(1H)-kinolin-4-on-forbindelser, en fremgangsmate for deres fremstilling og farmasoytisk sammensetninger inneholdende dem NO331618B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0207536A FR2841243B1 (fr)	2002-06-19	2002-06-19	Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2003/001849 WO2004000834A1 (fr)	2002-06-19	2003-06-18	Nouveaux derives de 3-(4-oxo-4h-chromen-2-yl)-(1h)-quinolein-4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number	Publication Date
NO20045540L NO20045540L (no)	2004-12-17
NO331618B1 true NO331618B1 (no)	2012-02-06

Family

ID=29719853

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20045540A NO331618B1 (no)	2002-06-19	2004-12-17	Nye 3-(4-okso-4H-kromen-2-yl)-(1H)-kinolin-4-on-forbindelser, en fremgangsmate for deres fremstilling og farmasoytisk sammensetninger inneholdende dem

Country Status (25)

Country	Link
US (1)	US7339061B2 (de)
EP (1)	EP1513833B1 (de)
JP (1)	JP4252035B2 (de)
KR (1)	KR100645138B1 (de)
CN (1)	CN1313462C (de)
AR (1)	AR040276A1 (de)
AT (1)	ATE323698T1 (de)
AU (1)	AU2003269003B2 (de)
BR (1)	BR0311956A (de)
CA (1)	CA2489136C (de)
DE (1)	DE60304703T2 (de)
DK (1)	DK1513833T3 (de)
EA (1)	EA008285B1 (de)
ES (1)	ES2263013T3 (de)
FR (1)	FR2841243B1 (de)
GE (1)	GEP20084296B (de)
MA (1)	MA27260A1 (de)
MX (1)	MXPA04012795A (de)
NO (1)	NO331618B1 (de)
NZ (1)	NZ537314A (de)
PL (1)	PL210722B1 (de)
PT (1)	PT1513833E (de)
UA (1)	UA78808C2 (de)
WO (1)	WO2004000834A1 (de)
ZA (1)	ZA200410048B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007130499A2 (en) *	2006-05-01	2007-11-15	Virobay, Inc.	Antiviral agents
FR2912145B1 (fr) *	2007-02-02	2009-03-06	Servier Lab	Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20190024983A (ko) *	2016-06-29	2019-03-08	오토노미, 인코포레이티드	트리글리세라이드 귀 제제 및 이의 용도
RU2642426C1 (ru) *	2017-03-21	2018-01-25	Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ИОС УрО РАН)	1-Этил-6-фтор-4-оксо-7-(8-этокси-2-оксо-2Н-хромен-3-ил)-1,4-дигидрохинолин-3-карбоновая кислота, обладающая противотуберкулезной активностью
CN112225744A (zh) *	2020-08-31	2021-01-15	兰州大学	一种6H-苯并吡喃并[3,4-b]喹啉类化合物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0733743A (ja) *	1993-07-22	1995-02-03	Kyorin Pharmaceut Co Ltd	２−アリール−４−キノリノール誘導体
CA2182932A1 (en) *	1995-08-10	1997-02-11	Koju Watanabe	Chromone derivative, process for preparing same and pharmaceutical composition
TW349948B (en) *	1995-10-31	1999-01-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 2-quinolone derivatives
DE19850131A1 (de) *	1998-10-30	2000-05-04	Merck Patent Gmbh	Chromenon- und Chromanonderivate

2002
- 2002-06-19 FR FR0207536A patent/FR2841243B1/fr not_active Expired - Fee Related
2003
- 2003-06-18 EP EP03750780A patent/EP1513833B1/de not_active Expired - Lifetime
- 2003-06-18 WO PCT/FR2003/001849 patent/WO2004000834A1/fr not_active Ceased
- 2003-06-18 DE DE60304703T patent/DE60304703T2/de not_active Expired - Lifetime
- 2003-06-18 ES ES03750780T patent/ES2263013T3/es not_active Expired - Lifetime
- 2003-06-18 EA EA200500028A patent/EA008285B1/ru not_active IP Right Cessation
- 2003-06-18 AT AT03750780T patent/ATE323698T1/de active
- 2003-06-18 UA UAA200500487A patent/UA78808C2/uk unknown
- 2003-06-18 JP JP2004514935A patent/JP4252035B2/ja not_active Expired - Fee Related
- 2003-06-18 BR BR0311956-4A patent/BR0311956A/pt not_active IP Right Cessation
- 2003-06-18 KR KR1020047020594A patent/KR100645138B1/ko not_active Expired - Fee Related
- 2003-06-18 AU AU2003269003A patent/AU2003269003B2/en not_active Ceased
- 2003-06-18 CA CA2489136A patent/CA2489136C/fr not_active Expired - Fee Related
- 2003-06-18 US US10/519,208 patent/US7339061B2/en not_active Expired - Fee Related
- 2003-06-18 PT PT03750780T patent/PT1513833E/pt unknown
- 2003-06-18 PL PL372984A patent/PL210722B1/pl not_active IP Right Cessation
- 2003-06-18 CN CNB038140500A patent/CN1313462C/zh not_active Expired - Fee Related
- 2003-06-18 GE GEAP20038592A patent/GEP20084296B/en unknown
- 2003-06-18 DK DK03750780T patent/DK1513833T3/da active
- 2003-06-18 MX MXPA04012795A patent/MXPA04012795A/es active IP Right Grant
- 2003-06-18 NZ NZ537314A patent/NZ537314A/en not_active IP Right Cessation
- 2003-06-19 AR ARP030102176A patent/AR040276A1/es active IP Right Grant
2004
- 2004-12-13 ZA ZA200410048A patent/ZA200410048B/xx unknown
- 2004-12-17 NO NO20045540A patent/NO331618B1/no not_active IP Right Cessation
2005
- 2005-01-18 MA MA28047A patent/MA27260A1/fr unknown

Also Published As

Publication number	Publication date
JP4252035B2 (ja)	2009-04-08
UA78808C2 (en)	2007-04-25
FR2841243A1 (fr)	2003-12-26
EP1513833A1 (de)	2005-03-16
ZA200410048B (en)	2006-07-26
FR2841243B1 (fr)	2004-08-20
BR0311956A (pt)	2005-03-29
EP1513833B1 (de)	2006-04-19
US20060063801A1 (en)	2006-03-23
EA200500028A1 (ru)	2005-06-30
AU2003269003B2 (en)	2009-05-28
EA008285B1 (ru)	2007-04-27
MXPA04012795A (es)	2005-02-24
PL210722B1 (pl)	2012-02-29
US7339061B2 (en)	2008-03-04
DE60304703T2 (de)	2007-04-05
WO2004000834A1 (fr)	2003-12-31
AU2003269003A1 (en)	2004-01-06
KR20050008833A (ko)	2005-01-21
DK1513833T3 (da)	2006-08-21
ES2263013T3 (es)	2006-12-01
GEP20084296B (en)	2008-01-25
AR040276A1 (es)	2005-03-23
PT1513833E (pt)	2006-07-31
NO20045540L (no)	2004-12-17
CA2489136C (fr)	2010-05-25
ATE323698T1 (de)	2006-05-15
KR100645138B1 (ko)	2006-11-10
PL372984A1 (en)	2005-08-08
CA2489136A1 (fr)	2003-12-31
JP2005533077A (ja)	2005-11-04
HK1081191A1 (en)	2006-05-12
CN1313462C (zh)	2007-05-02
NZ537314A (en)	2007-07-27
CN1692110A (zh)	2005-11-02
MA27260A1 (fr)	2005-03-01
DE60304703D1 (de)	2006-05-24

Legal Events

Date	Code	Title	Description
2015-01-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US5834476A (en)	1998-11-10	Hexa-cyclic compound
TWI829869B (zh)	2024-01-21	新型雜環三環衍生物化合物及其用途
DK2917217T3 (en)	2017-06-19	SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS
EA003272B1 (ru)	2003-02-27	Производные дигидро- и тетрагидрохинолина, способ их получения и содержащие их фармацевтические составы
FR3008975A1 (fr)	2015-01-30	Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003290119A1 (en)	2004-06-18	Sinomenine and sinomenine compounds, synthesis and use
JP3023990B2 (ja)	2000-03-21	カンプトテシン誘導体及びその製造方法
WO2012069856A1 (en)	2012-05-31	Antimalarial compounds
IE63492B1 (en)	1995-05-03	A Spiro Compound
WO2023001229A1 (zh)	2023-01-26	嘧啶并环类衍生物及其制备方法和用途
WO1999053924A1 (en)	1999-10-28	Analgetic agent
JP4252035B2 (ja)	2009-04-08	新しい３−（４−オキソ−４ｈ−クロメン−２−イル）−（１ｈ）−キノリン−４−オン化合物、その製造方法及びこれらを含む薬剤組成物
US6407115B1 (en)	2002-06-18	Hexa-cyclic compound
Blurton et al.	1997	Palladium catalysed coupling of iodoquinolines and acetylenes-a novel entry to the pyrrolo [3, 2, 1-ij]-quinoline nucleus
Al-Refai	2015	Synthesis, Characterization and Biological Evaluation of New 4-Aryl-6-(2, 5-dichlorothiophen-3-yl)-1, 2-dihydro-2-oxopyridine-3-carbonitrile
CN108948003B (zh)	2021-06-25	作为mTOR抑制剂的吡嗪并[2,3-c]喹啉-2（1H）-酮类化合物的制备及用途
EP0379529A1 (de)	1990-08-01	Antipsychotische gamma-carbolin-n-oxide
Aragon et al.	2007	Synthesis and biological evaluation of indoloquinolines and pyridocarbazoles: A new example of unexpected photoreduction accompanying photocyclization
Kiraly et al.	2008	Synthesis of cycloalkanoindoles, the carba analogs of physostigmine
CZ2002529A3 (cs)	2002-05-15	Derivát ascidideminu, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
EA007790B1 (ru)	2007-02-27	СОЕДИНЕНИЯ БЕНЗО [α]ПИРАНО[3,2-h]АКРИДИН-7-ОНА И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ
Voskressensky et al.	2008	Tandem transformations of 10-substituted tetrahydrobenzo [b][1, 6] naphthyridines resulted from the Michael addition of the nitrogen atom of the tetrahydropyridine fragment to the triple bond of activated alkynes
EP4367121A1 (de)	2024-05-15	Verbindung vom 7a,8,9,10,11,11a-hexahydro-1h,7h-pyrano[2,3-c!xanthen-typ, verfahren zu ihrer herstellung, zwischenprodukte und ihre therapeutische verwendung
HK40048411A (en)	2021-12-03	Macrocyclic tyrosine kinase inhibitor and uses thereof